Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2007-04-24
2007-04-24
Campell, Bruce R. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C514S616000
Reexamination Certificate
active
10144294
ABSTRACT:
This invention relates to methods and compositions directed towards the diagnosis and treatment of Hepatitis C virus infection and the screening of potential therapeutic compounds using novel small molecules based on imidazole-4,5-dicarboxylic acids scaffolds.
REFERENCES:
patent: 4552891 (1985-11-01), Ho et al.
patent: 5393773 (1995-02-01), Craig et al.
patent: 5554639 (1996-09-01), Craig et al.
patent: 5801161 (1998-09-01), Merkus
patent: 5864037 (1999-01-01), Chasin et al.
patent: 5869479 (1999-02-01), Kreutner et al.
Wagner, C.E. “Synthesis of 1-Boraadamantaneamine Derivatives with Selective Astrocyte vs C6 Glioma Antiproliferative Activity. A Novel Class of Anti-Hepatitis Agents with Potential to Bind CD81” J. Med. Chem (2003) vol. 46, pp. 2823-2833.
Chen, H. “Acyclic Nucleoside/Nucleotide Analogues With an Imidazole Ring Skeleton” Nucleos. Nucleot. & Nucliec Acids (2001 vol. 20, No. 8, pp. 1599-1614.
Aleksandrova, I. Ya., et al., “Investigation of the Conformations of the Diamides of Imidazole- and Pyrazoledicarboxylic Acids,”Zh. Org. Khim. 12:1109-1115, 1976.
Allander, T., et al., “Hepatitis C Virus Envelope Protein E2 Binds to CD81 of Tamarins,”Virology277:358-367, 2000.
Baures, P.W., et al., “Directed Intermolecular Association by Complementary Molecular Edges in 6-Methoxycoumarin,”Crystal Growth&Design2(2): 107-110, 2002.
Baures, P.W. “Heterocyclic HIV-1 Protease Inhibitors,”Organic Letters1:249-252, 1999.
Baures, P.W., et al., “Hydrogen Bonding Isosteres: Bimolecular Carboxylic Acid and Amine-N-oxcide Interactions Mediated Via CH . . . O Hydrogen Bonds,”Bioorganic&Medicinal Chemistry8: 1599-1605, 2000.
Clark, K. et al., “PGRL Is a Major CD81-Associated Protein on Lymphocytes and Distinguishes a New Family of Cell Surface Proteins,”The Journal of Immunology167:5115-5121, 2001.
Cochran, A., “Antagonists of protein—protein interactions,”Chemistry&Biology7:R85-R94, 2000.
Hadlock, K.G., et al., “Human Monoclonal Antibodies that Inhibit Binding of Hepatitis C Virus E2 Protein to CD81 and Recognize Conserved Conformational Epitopes,”J. Virol. 74:10407-10416, 2000.
Higginbottom, A., et al., “Identification of Amino Acid Residues in CD81 Critical for Interaction with Hepatitus C Virus Envelope Glycoprotein E2,”J. Virol. 74:3642-3649, 2000.
Janin, J. “Kinetics and Thermodynamics of Protein—Protein Interactions,” inProtein—Protein Recognition Kleanthous, C., Ed., 2000, pp. 1-32, Oxford University Press, Oxford.
Jones, S. and Thornton, J.M. “Analysis and Classification of Protein—Protein Interactions from a Structural Perspective” inProtein—Protein Recognition, Kleanthous, C., Ed., 2000, pp. 33-59, Oxford University Press, Oxford.
Kitadokoro, K., et al., “CD81 Extracellular Domain 3D Structure: Insight Into the Tetraspanin Superfamily Structural Motifs,”EMBO J. 20:12-18, 2001.
Levy, S., et al., “CD81 (TAPA-1): A Molecule Involved in Signal Transduction and Cell Adhesion in the Immune System,”Annu. Rev. Immunol. 16:89-109, 1998.
Ma, B., et al., “Protein Functional Epitopes: Hot Spots, Dynamics and Combinatorial Libraries,”Curr. Opin. Struct. Biol. 11:364-369, 2001.
Maecker, H.T., et al., “The Tetraspanin Family: Molecular Facilitators,”FASEB J. 11:428-442, 1997.
McCormick, F., “Small-molecule inhibitors of cell signaling,”Current Opinion in Biotechnology11:593-597, 2000.
Michnick, S.W. “Exploring Protein Interactions by Interaction-Induced Folding of proteins from Complementary Peptide Fragments,”Curr. Opin. Struct. Biol. 11:472-477, 2001.
Petracca, R., et al., “Structure-Function Analysis of Hepatitis C Virus Envelope-CD81 Binding,”J. Virol. 74:4824-4830, 2000.
Pileri, et al., “Binding of Hepatitis C Virus to CD81,”Science282:938-941, 1998.
Qin, J., et al., “Protein—Protein Interactions Probed by Nuclear Magnetic Resonance Spectroscopy,”Methods Enzymol. 339:377-389, 2001.
Teichmann, S.A., et al., “Determination of Protein Function, Evolution, and Interactions by Structural Genomics,”Curr. Opin. Struct. Biol. 11:354-363, 2001.
Todd, S. C., et al., “Sequences and Expression of Six New Members of the Tetraspanin/TMASF Family,”Biochim Ciophys Acta1399:101-104, 1998.
VanCompernolle, S.E., et al., “Anti-CD81 activates LFA-1 on T cells and promotes T cell-B cell collaboration,”Eur. J. Immunol. 31:823-831, 2001.
Wang, W., et al., “Biomolecular Simulations: Recent Developments in Force Fields, Simulations of Enzyme Catalysis, Protein-Ligand, Protein—Protein, and Protein-Nucleic Acid Noncovalent Interactions,”Annu. Rev. Biophys. Biomol. Struct. 30:211-243, 2001.
Wright, M.D. and Tomlinson, M.G. “The Ins and Outs of the Transmembrane 4 Superfamily,”Immunol. Today15:588-594, 1994.
Wünschmann, et al., “Characterization of Hepatitis C Virus (HCV) and HCV E2 Interactions with CD81 and the Low-Density Lipoprotein Receptor,”J. Virology74:10055-10062, 2000.
Yasuda, N. et al., “Intramolecular Hydrogen Bonding in Imidazole-4(5)-alkoxycarbonyl-5(4)-carboxamide Derivatives,”J. Het. Chem. 24:303-307, 1987.
Zutshi, R., et al., “Inhibiting the assembly of protein—protein interfaces,”Current Opinion In Chemical Biology2:62-66, 1998.
Baures Paul W.
Todd Scott C.
Campell Bruce R.
Horning Michelle
Kansas State University Research Foundation
LandOfFree
Compositions and methods for the treatment of hepatitis C... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of hepatitis C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of hepatitis C... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3756162